# Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting

> **NCT02176239** · — · COMPLETED · sponsor: **BriovaRx Infusion Services** · enrollment: 20 (estimated)

## Conditions studied

- Primary Immunodeficiency Disease (PIDD)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02176239
- **Lead sponsor:** BriovaRx Infusion Services
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02176239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02176239, "Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02176239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*